Compare PRGO & ADNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRGO | ADNT |
|---|---|---|
| Founded | 1887 | 2016 |
| Country | Ireland | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2013 | 2016 |
| Metric | PRGO | ADNT |
|---|---|---|
| Price | $10.25 | $20.73 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $19.33 | ★ $25.41 |
| AVG Volume (30 Days) | ★ 3.1M | 959.7K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | ★ 10.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | $800,000.00 | ★ $17,439,000,000.00 |
| Revenue This Year | N/A | $2.71 |
| Revenue Next Year | $1.02 | $2.36 |
| P/E Ratio | ★ N/A | $340.00 |
| Revenue Growth | N/A | ★ 7.56 |
| 52 Week Low | $9.23 | $17.68 |
| 52 Week High | $28.22 | $27.32 |
| Indicator | PRGO | ADNT |
|---|---|---|
| Relative Strength Index (RSI) | 47.76 | 52.56 |
| Support Level | $9.42 | $20.23 |
| Resistance Level | $11.72 | $23.72 |
| Average True Range (ATR) | 0.48 | 0.86 |
| MACD | -0.01 | 0.20 |
| Stochastic Oscillator | 31.94 | 55.05 |
Perrigo is one of the largest consumer health companies in the world. Since 2018, Perrigo has divested its animal health and generic pharmaceuticals businesses to solely focus on consumer self-care. In North America (two-thirds of total sales), the firm's product mix is anchored in private-label consumer health goods, which are sold to major retailers like Walmart, Amazon, Costco, and CVS. Perrigo also plays in Europe, Australia, and parts of Asia where it primarily generates revenue through its national brands, including Compeed, Solpadeine, Coldrex, and ellaOne.
Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.